Fernando Vieira Pericole

Fernando Vieira Pericole

Auto-generated profile, based on publicly available information

Fernando Vieira Pericole

Hemocentro, Universidade de Campinas UNICAMP, Campinas, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in Advances in Hematology
Verified
Journal Article
Open access
PDF file
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
DZDalila Luciola Zanette
Dalila Luciola Zanette
FPFernando Vieira Pericole
Fernando Vieira Pericole
SSSARA Teresinha OLALLA SAAD
SARA Teresinha OLALLA SAAD
JCJosé Carvalheira
José Carvalheira
Obesity is increasingly associated with the transformation of monoclonal gammopathy of undetermined significance (MGUS) into multiple myeloma (MM). Obesity, MGUS, and MM share common etiopathogenesis mechanisms including altered insulin axis and the action of inflammatory cytokines. Consistent with this interconnection, metformin could predominantly exert inhibition of these pathophysiological factors and thus be an attractive therapeutic option for MGUS. Despite the possible clinical significance, only a limited number of epidemiological studies have focused on obesity as a risk factor for MGUS and MM. This review describes multiple biological pathways modulated by metformin at the cellular level and their possible impacts on the biology of MGUS and its progression into MM.

29 March 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SSStephan P. M. Souza
Stephan P. M. Souza
FFFernanda C. Frasson
Fernanda C. Frasson
MTMaria Emilia Seren Takahashi
Maria Emilia Seren Takahashi
GDGislaine B. O. Duarte
Gislaine B. O. Duarte
VCVania P. Castro
Vania P. Castro
CRCelso Dario Ramos
Celso Dario Ramos

3 June 2024 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
MDMarcia Torresan Delamain
Marcia Torresan Delamain
ACAna Carolina Ferreira Cardoso
Ana Carolina Ferreira Cardoso
FPFernando Vieira Pericole
Fernando Vieira Pericole
SASérgio Shusterschitz da Silva Araújo
Sérgio Shusterschitz da Silva Araújo
LFLaura Fogliatto
Laura Fogliatto
VCVivienne Castilho
Vivienne Castilho
Introduction RTXM83, a biosimilar of rituximab, was approved after physicochemical, functional, non-clinical, and clinical studies demonstrated their similarity; these studies included RTXM83-AC-01-11, a multicentric double-blind international prospective pivotal study. Long-term data on biosimilars can potentially elucidate their clinical robustness and facilitate their broader adoption. Methods In this retrospective observational study, we analyzed a dataset from a Brazilian cohort previously randomized in the RTXM83-AC-01-11 study followed by the assessment of long-term outcomes in an observational extension phase from randomization in the RTXM83-AC-01–11 study to the last recorded evaluation. Patients with diffuse large B cell lymphoma (DLBCL) received either reference rituximab (R) or RTXM83 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as adjuvant treatment. Results The median follow-up period was 77.0 months. Patients with initial DLBCL stages III and IV comprised 50% of the R-CHOP group and 40% of the biosimilar group. Five (18.5%) patients, including two RTXM83-CHOP-treated and three R-CHOP-treated individuals, experienced late adverse events (AEs) of interest. No new safety signs were established. At the final assessment, the progression-free survival (PFS) rates were 93.3% and 50.0% in the RTXM83-CHOP and R-CHOP groups, respectively. Median PFS was not achieved in the RTXM83-CHOP group, which was 40.5 months in the R-CHOP group. The overall survival (OS) rates were 100% and 66.7% in the RTXM83-CHOP and R-CHOP groups, respectively. The median OS was not reached in any group. Conclusion This study demonstrated the long-term safety and effectiveness of RTXM83 in treating DLBCL; outcomes comparable to those of the reference product and potentially improved access to treatment have been indicated. However, further research with more diverse patient groups can validate these findings and advocate the broader adoption of biosimilars in cancer care. Trial Registration ClinicalTrials.gov Identifier: NCT04928573. June 16, 2021, “retrospectively registered”.